Nuvectis Pharma to Participate in the 37th Annual Roth Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 14 2025
0mins
Source: Newsfilter
Company Announcement: Nuvectis Pharma, Inc. will have its CEO Ron Bentsur participate in a fireside chat at the 37th Annual Roth Conference from March 17-19, 2025, in Dana Point, California.
About Nuvectis Pharma: The company is focused on developing precision medicines for oncology, currently working on two clinical-stage drug candidates, NXP800 and NXP900, targeting specific cancer types with innovative mechanisms of action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVCT
Wall Street analysts forecast NVCT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.590
Low
10.00
Averages
15.67
High
20.00
Current: 12.590
Low
10.00
Averages
15.67
High
20.00
About NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator that has been evaluated in a Phase Ib clinical trial for the treatment of platinum-resistant, ARID1a-mutated ovarian cancer, and it is exploring other development opportunities for NXP800. Chronic activation of GCN2 by NXP800 leads to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is in the Phase Ib program. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers. YES1 is a nonreceptor tyrosine kinase that belongs to the SRC family of kinases and controls multiple cancer signaling pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Show Strong Stock Performance
- Butterfly Network Stock Surge: Butterfly Network's stock has risen 304% since publication, currently priced at $8.90, driven by the successful application of its Ultrasound-on-Chip technology and collaboration with Midjourney, with a full-body imaging system launch expected to boost market demand.
- Nuvectis Pharma Significant Progress: Nuvectis's NXP900 clinical program is advancing at top US hospitals, with a stock price increase of 104%, currently at $13.82, and preliminary data expected this summer, likely attracting investor interest.
- Trevi Therapeutics Clinical Trial Success: Trevi's Haduvio drug achieved positive results in the Phase 2b CORAL trial, with a stock price increase of 167%, currently at $17.21, and plans for two Phase 3 trials in 2026, indicating strong market potential.
- BrightSpring Health Service Growth: BrightSpring's stock has risen 291% since publication, currently priced at $66.25, as the company's operational and financial performance has drawn investor attention, with second-quarter results due in August, potentially revising 2026 revenue guidance upward.
See More
Nuvectis Pharma to Present at BioConnect Investor Conference
- Investor Conference Participation: Nuvectis Pharma will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York, showcasing its innovative drug development in oncology, which is expected to attract investor interest and enhance the company's visibility.
- Management Presentation: CEO Ron Bentsur will deliver a 30-minute presentation at the conference, detailing the clinical progress of NXP900, aiming to bolster investor confidence through an in-depth explanation of its unique mechanism of action.
- NXP900 Development Progress: NXP900 is an oral small molecule inhibitor targeting SRC family kinases, having completed a Phase 1a dose escalation study and currently undergoing the Phase 1b program, indicating promising clinical prospects.
- Webcast Availability: The presentation will be available via webcast on Nuvectis' investor section of its website, ensuring that investors unable to attend in person can stay updated on the company's latest developments, thereby enhancing transparency and investor relations.
See More
Nuvectis Pharma Reports Q1 2026 Financial Results and NXP900 Update
- Clinical Progress Update: Nuvectis Pharma's NXP900 Phase 1b clinical program continues to enroll patients at top sites in the US, indicating steady advancement in the development of innovative oncology treatments, with preliminary data expected in summer that could positively impact future clinical trials and market positioning.
- Financial Overview: As of March 31, 2026, the company reported cash and cash equivalents of $25.1 million, down from $31.6 million as of December 31, 2025, reflecting the company's funding utilization in R&D and operations, which may influence future fundraising strategies.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $4.1 million, up from $3.7 million in Q1 2025, primarily driven by rising manufacturing costs and employee compensation, a trend that could affect the company's financial health and investor confidence.
- Widening Net Loss: The company reported a net loss of $6.1 million for Q1 2026, compared to a loss of $5.3 million in Q1 2025, highlighting ongoing challenges in profitability despite continued investment in clinical development, which may negatively impact shareholder return expectations.
See More
NUVECTIS PHARMA, INC. ANNOUNCES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FIRST QUARTER 2026
Financial Performance: Nuvectis Pharma, Inc. reported its financial results for the first quarter of 2026, highlighting key metrics and performance indicators.
Business Highlights: The report includes significant business developments and achievements that occurred during the quarter, showcasing the company's progress and strategic initiatives.
See More
Nuvectis Pharma Reports FY GAAP EPS of -$1.32
- Financial Performance: Nuvectis Pharma reported a FY GAAP EPS of -$1.32, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $31.6 million, an increase of $13.1 million from $18.5 million on December 31, 2024, reflecting some progress in financing.
- Funding Sources: The cash increase was primarily driven by the February 2025 public offering and access to the at-the-market facility, although rising operating expenses have partially offset this growth.
- Market Reaction: Despite the improvement in cash position, ongoing losses may negatively impact the stock price, prompting investors to closely monitor future profitability and cash flow management.
See More
Nuvectis Pharma Reports 2025 Financial Results and Business Progress
- Financial Overview: As of December 31, 2025, Nuvectis reported cash and cash equivalents of $31.6 million, up from $18.5 million in 2024, primarily due to a public offering in February 2025, despite rising operating expenses.
- Increased Net Loss: The company's net loss for 2025 was $26.4 million, an increase of $7.4 million from $19.0 million in 2024, reflecting higher R&D and administrative costs, including $6.0 million in non-cash stock-based compensation and $2.4 million in one-time license fees.
- R&D Spending Growth: Research and development expenses reached $18.2 million in 2025, up from $12.9 million in 2024, indicating the company's ongoing investment in the NXP900 program aimed at advancing its clinical trials.
- Positive Future Outlook: Nuvectis anticipates 2026 to be a pivotal year with multiple clinical data readouts for NXP900 expected, as the company remains focused on operational execution and financial responsibility to support future milestones.
See More
Multiple Companies Show Strong Stock Performance
- Butterfly Network Stock Surge: Butterfly Network's stock has risen 304% since publication, currently priced at $8.90, driven by the successful application of its Ultrasound-on-Chip technology and collaboration with Midjourney, with a full-body imaging system launch expected to boost market demand.
- Nuvectis Pharma Significant Progress: Nuvectis's NXP900 clinical program is advancing at top US hospitals, with a stock price increase of 104%, currently at $13.82, and preliminary data expected this summer, likely attracting investor interest.
- Trevi Therapeutics Clinical Trial Success: Trevi's Haduvio drug achieved positive results in the Phase 2b CORAL trial, with a stock price increase of 167%, currently at $17.21, and plans for two Phase 3 trials in 2026, indicating strong market potential.
- BrightSpring Health Service Growth: BrightSpring's stock has risen 291% since publication, currently priced at $66.25, as the company's operational and financial performance has drawn investor attention, with second-quarter results due in August, potentially revising 2026 revenue guidance upward.
See More
Nuvectis Pharma to Present at BioConnect Investor Conference
- Investor Conference Participation: Nuvectis Pharma will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York, showcasing its innovative drug development in oncology, which is expected to attract investor interest and enhance the company's visibility.
- Management Presentation: CEO Ron Bentsur will deliver a 30-minute presentation at the conference, detailing the clinical progress of NXP900, aiming to bolster investor confidence through an in-depth explanation of its unique mechanism of action.
- NXP900 Development Progress: NXP900 is an oral small molecule inhibitor targeting SRC family kinases, having completed a Phase 1a dose escalation study and currently undergoing the Phase 1b program, indicating promising clinical prospects.
- Webcast Availability: The presentation will be available via webcast on Nuvectis' investor section of its website, ensuring that investors unable to attend in person can stay updated on the company's latest developments, thereby enhancing transparency and investor relations.
See More
Nuvectis Pharma Reports Q1 2026 Financial Results and NXP900 Update
- Clinical Progress Update: Nuvectis Pharma's NXP900 Phase 1b clinical program continues to enroll patients at top sites in the US, indicating steady advancement in the development of innovative oncology treatments, with preliminary data expected in summer that could positively impact future clinical trials and market positioning.
- Financial Overview: As of March 31, 2026, the company reported cash and cash equivalents of $25.1 million, down from $31.6 million as of December 31, 2025, reflecting the company's funding utilization in R&D and operations, which may influence future fundraising strategies.
- Increased R&D Expenses: Research and development expenses for Q1 2026 reached $4.1 million, up from $3.7 million in Q1 2025, primarily driven by rising manufacturing costs and employee compensation, a trend that could affect the company's financial health and investor confidence.
- Widening Net Loss: The company reported a net loss of $6.1 million for Q1 2026, compared to a loss of $5.3 million in Q1 2025, highlighting ongoing challenges in profitability despite continued investment in clinical development, which may negatively impact shareholder return expectations.
See More
NUVECTIS PHARMA, INC. ANNOUNCES FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS FOR FIRST QUARTER 2026
Financial Performance: Nuvectis Pharma, Inc. reported its financial results for the first quarter of 2026, highlighting key metrics and performance indicators.
Business Highlights: The report includes significant business developments and achievements that occurred during the quarter, showcasing the company's progress and strategic initiatives.
See More
Nuvectis Pharma Reports FY GAAP EPS of -$1.32
- Financial Performance: Nuvectis Pharma reported a FY GAAP EPS of -$1.32, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, the company had cash and cash equivalents of $31.6 million, an increase of $13.1 million from $18.5 million on December 31, 2024, reflecting some progress in financing.
- Funding Sources: The cash increase was primarily driven by the February 2025 public offering and access to the at-the-market facility, although rising operating expenses have partially offset this growth.
- Market Reaction: Despite the improvement in cash position, ongoing losses may negatively impact the stock price, prompting investors to closely monitor future profitability and cash flow management.
See More
Nuvectis Pharma Reports 2025 Financial Results and Business Progress
- Financial Overview: As of December 31, 2025, Nuvectis reported cash and cash equivalents of $31.6 million, up from $18.5 million in 2024, primarily due to a public offering in February 2025, despite rising operating expenses.
- Increased Net Loss: The company's net loss for 2025 was $26.4 million, an increase of $7.4 million from $19.0 million in 2024, reflecting higher R&D and administrative costs, including $6.0 million in non-cash stock-based compensation and $2.4 million in one-time license fees.
- R&D Spending Growth: Research and development expenses reached $18.2 million in 2025, up from $12.9 million in 2024, indicating the company's ongoing investment in the NXP900 program aimed at advancing its clinical trials.
- Positive Future Outlook: Nuvectis anticipates 2026 to be a pivotal year with multiple clinical data readouts for NXP900 expected, as the company remains focused on operational execution and financial responsibility to support future milestones.
See More
